全文总字数：4981字

1. 1. 毕业设计（论文）的内容、要求、设计方案、规划等

（1）前言：对聚戊烯醇的理化特性、现阶段加工现状做简要综述，了解近年来国内外相关产品的开发利用及生产研究现状，提出本研究改性产品后如何增加其水溶性及后续对合成产物结构表征研究的工作，同时阐明本研究的目的及意义。

（2）方案拟定：利用氨基/氰基改性聚戊烯醇增加其水溶性，然后再与钌多吡啶部分反应得到聚戊烯醇钌配合物，并利用红外、核磁等手段对合成过程中的产物进行结构表征。

（3）实验数据采集与处理：实验数据的分析处理主要包括红外以及核磁分析软件等。

2. 参考文献（不低于12篇）

[1] han ang, w.; dyson, p.j., classical andnon-classical ruthenium-basedanticancer drugs: towards targeted chemotherapy. eur. j. inorg. chem., 2006,20, 4003-4018.

[2] (a) zhang, y.; guo, z.;you, x.z., hydrolysis theory for cisplatin and its analogues based on densityfunctional studies. j. am. chem. soc.,2001,123, 9378-9387; (b) reedijk, j.,improved understanding in platinium antitumour chemistry. chem. commun.,1996,7,801-806;(c) ohndorf, u.m.; rould, m. a.; he, q.; pabo, c. o.; lippard, s. j., basis forrecognition of cisplatin-modified dna by high-mobility-group proteins. nature,1999,399, 708-712; (d) reedijk, j.,platinum anticancer coordination compounds: study of dna binding inspires newdrug design. eur. j. inorg. chem.,2009,10,1303-1312.

[3] (a) wong, e.;giandomenico, c. m., current status of platinum-based antitumor drugs. chem.rev.,1999,99, 2451-2466;(b) galanski, m.; jakupec, m. a.; keppler, b. k., update of the preclinicalsituation of anticancer platinum complexes: novel design strategies andinnovative analytical approaches. curr. med. chem.,2005,12, 2075-2094; (c)keppler, b. k., metalcomplexes in cancer chemotherapy. wiley-vch: 1993.